Clinical Development Updates
Destiny Pharma has started the year with two important clinical development updates on its lead products which enhance both their profiles.The clinical development update on XF-73 Dermal, which is a variation on Destiny’s XF-73 Nasal product included a preclinical study of an XF-73 Dermal formulation demonstrating that like XF-73 Nasal, it is also safe and applications to wounds results in negligible systemic levels.
On the non-toxigenic Clostridioides difficile strain M3, Destiny and partner Sebela Pharmaceuticals improved M3’s chemistry, manufacturing and controls program to incorporate a solid dose, rather than liquid formulation – which should improve patient compliance, manufacturing and storage costs – and changed the product’s contract manufacturer. While these changes may necessitate a bridging study between the two dosage forms, the costs all future M3 studies will be met by Destiny’s partner.
Our fair value remains unchanged at £245.7m, or 279 pence per share.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.